Search

Your search keyword '"Braconi, C."' showing total 207 results
Start Over Author "Braconi, C."
207 results on '"Braconi, C."'

2. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

Author

Calvisi, D, Boulter, L, Vaquero, J, Saborowski, A, Fabris, L, Rodrigues, P, Coulouarn, C, Castro, R, Segatto, O, Raggi, C, van der Laan, L, Carpino, G, Goeppert, B, Roessler, S, Kendall, T, Evert, M, Gonzalez-Sanchez, E, Valle, J, Vogel, A, Bridgewater, J, Borad, M, Gores, G, Roberts, L, Marin, J, Andersen, J, Alvaro, D, Forner, A, Banales, J, Cardinale, V, Macias, R, Vicent, S, Chen, X, Braconi, C, Verstegen, M, Fouassier, L, Scheiter, A, Selaru, F, Evert, K, Utpatel, K, Broutier, L, Cadamuro, M, Huch, M, Goldin, R, Gradilone, S, Saito, Y, Calvisi D. F., Boulter L., Vaquero J., Saborowski A., Fabris L., Rodrigues P. M., Coulouarn C., Castro R. E., Segatto O., Raggi C., van der Laan L. J. W., Carpino G., Goeppert B., Roessler S., Kendall T. J., Evert M., Gonzalez-Sanchez E., Valle J. W., Vogel A., Bridgewater J., Borad M. J., Gores G. J., Roberts L. R., Marin J. J. G., Andersen J. B., Alvaro D., Forner A., Banales J. M., Cardinale V., Macias R. I. R., Vicent S., Chen X., Braconi C., Verstegen M. M. A., Fouassier L., Roberts L., Scheiter A., Selaru F. M., Evert K., Utpatel K., Broutier L., Cadamuro M., Huch M., Goldin R., Gradilone S. A., Saito Y., Calvisi, D, Boulter, L, Vaquero, J, Saborowski, A, Fabris, L, Rodrigues, P, Coulouarn, C, Castro, R, Segatto, O, Raggi, C, van der Laan, L, Carpino, G, Goeppert, B, Roessler, S, Kendall, T, Evert, M, Gonzalez-Sanchez, E, Valle, J, Vogel, A, Bridgewater, J, Borad, M, Gores, G, Roberts, L, Marin, J, Andersen, J, Alvaro, D, Forner, A, Banales, J, Cardinale, V, Macias, R, Vicent, S, Chen, X, Braconi, C, Verstegen, M, Fouassier, L, Scheiter, A, Selaru, F, Evert, K, Utpatel, K, Broutier, L, Cadamuro, M, Huch, M, Goldin, R, Gradilone, S, Saito, Y, Calvisi D. F., Boulter L., Vaquero J., Saborowski A., Fabris L., Rodrigues P. M., Coulouarn C., Castro R. E., Segatto O., Raggi C., van der Laan L. J. W., Carpino G., Goeppert B., Roessler S., Kendall T. J., Evert M., Gonzalez-Sanchez E., Valle J. W., Vogel A., Bridgewater J., Borad M. J., Gores G. J., Roberts L. R., Marin J. J. G., Andersen J. B., Alvaro D., Forner A., Banales J. M., Cardinale V., Macias R. I. R., Vicent S., Chen X., Braconi C., Verstegen M. M. A., Fouassier L., Roberts L., Scheiter A., Selaru F. M., Evert K., Utpatel K., Broutier L., Cadamuro M., Huch M., Goldin R., Gradilone S. A., and Saito Y.

Abstract

Cholangiocarcinoma (CCA) is a rare malignancy that develops at any point along the biliary tree. CCA has a poor prognosis, its clinical management remains challenging, and effective treatments are lacking. Therefore, preclinical research is of pivotal importance and necessary to acquire a deeper understanding of CCA and improve therapeutic outcomes. Preclinical research involves developing and managing complementary experimental models, from in vitro assays using primary cells or cell lines cultured in 2D or 3D to in vivo models with engrafted material, chemically induced CCA or genetically engineered models. All are valuable tools with well-defined advantages and limitations. The choice of a preclinical model is guided by the question(s) to be addressed; ideally, results should be recapitulated in independent approaches. In this Consensus Statement, a task force of 45 experts in CCA molecular and cellular biology and clinicians, including pathologists, from ten countries provides recommendations on the minimal criteria for preclinical models to provide a uniform approach. These recommendations are based on two rounds of questionnaires completed by 35 (first round) and 45 (second round) experts to reach a consensus with 13 statements. An agreement was defined when at least 90% of the participants voting anonymously agreed with a statement. The ultimate goal was to transfer basic laboratory research to the clinics through increased disease understanding and to develop clinical biomarkers and innovative therapies for patients with CCA.

Published
2023

3. Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice

Author

Moorcraft, S.Y., Gonzalez de Castro, D., Cunningham, D., Jones, T., Walker, B.A., Peckitt, C., Yuan, L.C., Frampton, M., Begum, R., Eltahir, Z., Wotherspoon, A., Teixeira Mendes, L.S., Hulkki Wilson, S., Gillbanks, A., Baratelli, C., Fotiadis, N., Patel, A., Braconi, C., Valeri, N., Gerlinger, M., Rao, S., Watkins, D., Chau, I., and Starling, N.

Published
2018
Full Text
View/download PDF

4. Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer

Author

Lote, H., Spiteri, I., Ermini, L., Vatsiou, A., Roy, A., McDonald, A., Maka, N., Balsitis, M., Bose, N., Simbolo, M., Mafficini, A., Lampis, A., Hahne, J.C., Trevisani, F., Eltahir, Z., Mentrasti, G., Findlay, C., Kalkman, E.A.J., Punta, M., Werner, B., Lise, S., Aktipis, A., Maley, C., Greaves, M., Braconi, C., White, J., Fassan, M., Scarpa, A., Sottoriva, A., and Valeri, N.

Published
2017
Full Text
View/download PDF

6. Heterogeneity of Cholangiocarcinoma immune biology

Author

Vita, F. (Francesca), Olaizola, I. (Irene), Amato, F. (Francesco), Rae, C. (Colin), Marco, S. (Sergi), Banales, J.M. (Jesús M.), and Braconi, C. (Chiara)

Subjects
Cancer stem cells, Immune cells, Advanced biliary cancer, Dendritic cells, Cholangiocarcinoma, Matrix metalloproteinases, Liver, Tumor microenvironment, Hepatic stellate cells, Mesenchymal transition, Hepatocellular-carcinoma, Heterogeneity, Cancer-associated fibroblasts, Neutrophil-lymphocyte ratio, Intrahepatic cholangiocarcinoma
Abstract

Cholangiocarcinomas (CCAs) are aggressive tumors arising along the biliary tract epithelium, whose incidence and mortality are increasing. CCAs are highly desmoplastic cancers characterized by a dense tumor microenvironment (TME), in which each single component plays a fundamental role in shaping CCA initiation, progression and resistance to therapies. The crosstalk between cancer cells and TME can affect the recruitment, infiltration and differentiation of immune cells. According to the stage of the disease and to intra- and inter-patient heterogeneity, TME may contribute to either protumoral or antitumoral activities. Therefore, a better understanding of the effect of each immune cell subtype may open the path to new personalized immune therapeutic strategies for the management of CCA. In this review, we describe the role of immune cells in CCA initiation and progression, and their crosstalk with both cancer-associated fibroblasts (CAFs) and the cancer-stem-cell-like (CSC) niche.

Published
2023

7. Cholangiocarcinoma 2020: the next horizon in mechanisms and management

Author

Banales, J, Marin, J, Lamarca, A, Rodrigues, P, Khan, S, Roberts, L, Cardinale, V, Carpino, G, Andersen, J, Braconi, C, Calvisi, D, Perugorria, M, Fabris, L, Boulter, L, Macias, R, Gaudio, E, Alvaro, D, Gradilone, S, Strazzabosco, M, Marzioni, M, Coulouarn, C, Fouassier, L, Raggi, C, Invernizzi, P, Mertens, J, Moncsek, A, Rizvi, S, Heimbach, J, Koerkamp, B, Bruix, J, Forner, A, Bridgewater, J, Valle, J, Gores, G, Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ, Banales, J, Marin, J, Lamarca, A, Rodrigues, P, Khan, S, Roberts, L, Cardinale, V, Carpino, G, Andersen, J, Braconi, C, Calvisi, D, Perugorria, M, Fabris, L, Boulter, L, Macias, R, Gaudio, E, Alvaro, D, Gradilone, S, Strazzabosco, M, Marzioni, M, Coulouarn, C, Fouassier, L, Raggi, C, Invernizzi, P, Mertens, J, Moncsek, A, Rizvi, S, Heimbach, J, Koerkamp, B, Bruix, J, Forner, A, Bridgewater, J, Valle, J, Gores, G, Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, and Gores GJ

Abstract

Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant tumours that can arise at any point of the biliary tree. Their incidence is increasing globally, currently accounting for ~15% of all primary liver cancers and ~3% of gastrointestinal malignancies. The silent presentation of these tumours combined with their highly aggressive nature and refractoriness to chemotherapy contribute to their alarming mortality, representing ~2% of all cancer-related deaths worldwide yearly. The current diagnosis of CCA by non-invasive approaches is not accurate enough, and histological confirmation is necessary. Furthermore, the high heterogeneity of CCAs at the genomic, epigenetic and molecular levels severely compromises the efficacy of the available therapies. In the past decade, increasing efforts have been made to understand the complexity of these tumours and to develop new diagnostic tools and therapies that might help to improve patient outcomes. In this expert Consensus Statement, which is endorsed by the European Network for the Study of Cholangiocarcinoma, we aim to summarize and critically discuss the latest advances in CCA, mostly focusing on classification, cells of origin, genetic and epigenetic abnormalities, molecular alterations, biomarker discovery and treatments. Furthermore, the horizon of CCA for the next decade from 2020 onwards is highlighted.

Published
2020

8. Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Resected Perihilar Cholangiocarcinoma, the ENS-CCA Registry

Author

Nooijen, L.E., primary, Bañales, J., additional, de Boer, M.T., additional, Braconi, C., additional, Folseraas, T., additional, Forner, A., additional, Holowko, W., additional, Hoogwater, F.J.H., additional, Klümpen, H.-J., additional, Groot-Koerkamp, B., additional, Lamarca, A., additional, Landa-Magdalena, A., additional, López-López, F., additional, Sánchez, L. Izquierdo, additional, Scheiter, A., additional, Utpatel, K., additional, Swijnenburg, R.-J., additional, and Erdmann, J.I., additional

Published
2022
Full Text
View/download PDF

10. 59TiP Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)

Author

Knox, J., primary, McNamara, M.G., additional, Goyal, L., additional, Cosgrove, D., additional, Springfeld, C., additional, Sjoquist, K., additional, Park, J.O., additional, Verdaguer, H., additional, Braconi, C., additional, Ross, P., additional, Oh, D-Y., additional, De Gramont, A., additional, Shroff, R.T., additional, Zalcberg, J.R., additional, Palmer, D., additional, and Valle, J.W., additional

Published
2021
Full Text
View/download PDF

14. The impact of gender and immune system determinants on long-term survival in biliary tract cancer

Author

Salati M., Caputo F., Cerma K., Marcheselli L., Braconi C., Cascinu S., Salati, M., Caputo, F., Cerma, K., Marcheselli, L., Braconi, C., and Cascinu, S.

Subjects
Biliary tract cancer, Gender differences, Immune system determnants
Abstract

Advanced biliary tract cancers are poor prognosis tumors with limited therapeutic options. The conven-tional treatment consists of combination chemotherapy resulting in overall survival of less than 12 months. Recently, a subgroup of patients characterized by an exceedingly fa-vorable prognosis has been reported in the literature. In our study, we assessed the prevalence and provided a clinico-pathological characterization of this subset of patients in the context of daily practice. In particular, we were able to identify female sex and neutrophil-to-lymphocyte ratio as independent predictors of long-term survival. Based on these premises, we deem it necessary to prompt transla-tional research projects aimed at molecularly characterized long-term survivors, particularly focusing on sex-and im-mune-related determinants.

Published
2019

15. Cholangiocarcinoma 2020: the next horizon in mechanisms and management

Author

Banales, J.M., Marin, J.J.G., LaMarca, A., Rodrigues, P.M., Khan, S.A., Roberts, L.R., Cardinale, V., Carpino, G., Andersen, J.B., Braconi, C., Calvisi, D.F., Perugorria, M.J., Fabris, L., Boulter, L, Macias, R.I.R., Gaudio, E., Alvaro, D., Gradilone, S.A., Strazzabosco, M, Marzioni, M., Coulouarn, C., Fouassier, L., Raggi, C., Invernizzi, P, Mertens, J.C., Moncsek, A., Rizvi, S., Heimbach, J., Groot Koerkamp, B. (Bas), Bruix, J. (J.), Forner, A., Bridgewater, J., Valle, J.W., Gores, G.J. (Gregory), Banales, J.M., Marin, J.J.G., LaMarca, A., Rodrigues, P.M., Khan, S.A., Roberts, L.R., Cardinale, V., Carpino, G., Andersen, J.B., Braconi, C., Calvisi, D.F., Perugorria, M.J., Fabris, L., Boulter, L, Macias, R.I.R., Gaudio, E., Alvaro, D., Gradilone, S.A., Strazzabosco, M, Marzioni, M., Coulouarn, C., Fouassier, L., Raggi, C., Invernizzi, P, Mertens, J.C., Moncsek, A., Rizvi, S., Heimbach, J., Groot Koerkamp, B. (Bas), Bruix, J. (J.), Forner, A., Bridgewater, J., Valle, J.W., and Gores, G.J. (Gregory)

Abstract

Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant tumours that can arise at any point of the biliary tree. Their incidence is increasing globally, currently accounting for ~15% of all primary liver cancers and ~3% of gastrointestinal malignancies. The silent presentation of these tumours combined with their highly aggressive nature and refractoriness to chemotherapy contribute to their alarming mortality, representing ~2% of all cancer-related deaths worldwide yearly. The current diagnosis of CCA by non-invasive approaches is not accurate enough, and histological confirmation is necessary. Furthermore, the high heterogeneity of CCAs at the genomic, epigenetic and molecular levels severely compromises the efficacy of the available therapies. In the past decade, increasing efforts have been made to understand the complexity of these tumours and to develop new diagnostic tools and therapies that might help to improve patient outcomes. In this expert Consensus Statement, which is endorsed by the European Network for the Study of Cholangiocarcinoma, we aim to summarize and critically discuss the latest advances in CCA, mostly focusing on classification, cells of origin, genetic and epigenetic abnormalities, molecular alterations, biomarker discovery and treatments. Furthermore, the horizon of CCA for the next decade from 2020 onwards is highlighted.

Published
2020
Full Text
View/download PDF

16. Cholangiocarcinoma 2020: the next horizon in mechanisms and management

Author

Banales, JM, Marin, JJG, LaMarca, A, Rodrigues, PM, Khan, SA, Roberts, LR, Cardinale, V, Carpino, G, Andersen, JB, Braconi, C, Calvisi, DF, Perugorria, MJ, Fabris, L, Boulter, L, Macias, RIR, Gaudio, E, Alvaro, D, Gradilone, SA, Strazzabosco, M, Marzioni, M, Coulouarn, C, Fouassier, L, Raggi, C, Invernizzi, P, Mertens, JC, Moncsek, A, Rizvi, S, Heimbach, J, Groot Koerkamp, B, Bruix, J, Forner, A, Bridgewater, J, Valle, JW, Gores, GJ, Banales, JM, Marin, JJG, LaMarca, A, Rodrigues, PM, Khan, SA, Roberts, LR, Cardinale, V, Carpino, G, Andersen, JB, Braconi, C, Calvisi, DF, Perugorria, MJ, Fabris, L, Boulter, L, Macias, RIR, Gaudio, E, Alvaro, D, Gradilone, SA, Strazzabosco, M, Marzioni, M, Coulouarn, C, Fouassier, L, Raggi, C, Invernizzi, P, Mertens, JC, Moncsek, A, Rizvi, S, Heimbach, J, Groot Koerkamp, B, Bruix, J, Forner, A, Bridgewater, J, Valle, JW, and Gores, GJ

Published
2020

19. 80TiP Global phase III study of NUC-1031 plus cisplatin vs gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)

Author

Knox, J.J., primary, McNamara, M.G., additional, Goyal, L., additional, Doherty, M., additional, Cosgrove, D., additional, Springfeld, C., additional, Sjoquist, K., additional, Park, J.O., additional, Verdaguer, H., additional, Braconi, C., additional, Ross, P., additional, De Gramont, A., additional, Zalcberg, J.R., additional, Palmer, D., additional, and Valle, J.W., additional

Published
2020
Full Text
View/download PDF

20. Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of response to DNA damage

Author

Lampis, A., primary, Carotenuto, P., additional, Hedayat, S., additional, Previdi, M.C., additional, Zito, D., additional, Sclafani, F., additional, Parisi, C., additional, Hahne, J.C., additional, Hallsworth, A., additional, Kirkin, V., additional, Young, K., additional, Kouvelakis, K., additional, Azevedo, S.X., additional, Vasiliki, M., additional, Scarpa, A., additional, Cunningham, D., additional, Chau, I., additional, Valeri, N., additional, Fassan, M., additional, and Braconi, C., additional

Published
2019
Full Text
View/download PDF

22. Liver metastases (LM) from intrahepatic cholangiocarcinoma (iCCA): Outcomes from the European Network for the study of cholangiocarcinoma (ENS-CCA) registry and implications on current American Joint Committee on Cancer (AJCC) staging

Author

Lamarca, A., primary, Santos, A., additional, Utpatel, K., additional, La Casta, A., additional, Stock, S., additional, Forner, A., additional, Adeva Alfonso, J., additional, Folseraas, T., additional, Fabris, L., additional, Macias, R., additional, Krawczyk, M., additional, Cardinale, V., additional, Braconi, C., additional, Alvaro, D., additional, Evert, M., additional, Bañales, J., additional, and Valle, J.W., additional

Published
2019
Full Text
View/download PDF

23. Identification of a nanostring signature that differentiates early pancreatic cancers according to stromal composition and predicts clinical outcome

Author

Sclafani, F., primary, Cascione, L., additional, Cunningham, D., additional, Young, K., additional, Carotenuto, P., additional, Fassan, M., additional, Salati, M., additional, Lanese, A., additional, Berenguer Pina, J., additional, Kouvelakis, K., additional, Vendrell, I., additional, Said-Huntingford, I., additional, Previdi, M., additional, Begum, R., additional, Gillbanks, A., additional, Hedayat, S., additional, Sadanandam, A., additional, Lampis, A., additional, Hahne, J., additional, Valeri, N., additional, Chau, I., additional, and Braconi, C., additional

Published
2019
Full Text
View/download PDF

24. MicroRNAs: nuovi biomarcatori predittivi di sviluppo di insufficienza renale cronica e ipertensione arteriosa nei pazienti sottoposti a nefrectomia radicale per carcinoma renale

Author

TREVISANI F, GHIDINI M, HAHNE J, LAMPIS A, SCIARRONE ALIBRANDI MT, ZAGATO L, CITTERIO L, DELL’ANTONIO G, MONTORSI, FRANCESCO, BERTINI R, SALONIA, ANDREA, BRIGANTI A, BENIGNI F, CARENZI C, CAPASSO GB, RUGGE M, FASSAN M, RIGOTTI P, CASCIONE L, BRACONI C, VALERI N., MANUNTA , PAOLO, Trevisani, F, Ghidini, M, Hahne, J, Lampis, A, Manunta, Paolo, SCIARRONE ALIBRANDI, Mt, Zagato, L, Citterio, L, Dell’Antonio, G, Montorsi, Francesco, Bertini, R, Salonia, Andrea, Briganti, A, Benigni, F, Carenzi, C, Capasso, Gb, Rugge, M, Fassan, M, Rigotti, P, Cascione, L, Braconi, C, and Valeri, N.

Published
2015

25. MicroRNAs as predictive biomarkers of chronic kidney disease (CKD) in patients (pts) undergoing radical nephrectomy (RN) for kidney cancer

Author

TREVISANI F, GHIDINI M, HAHNE J, LAMPIS A, SCIARRONE ALIBRANDI MT, ZAGATO L, CITTERIO L, DELL’ANTONIO G, MONTORSI, FRANCESCO, BERTINI R, SALONIA, ANDREA, BRIGANTI A, BENIGNI F, CARENZI C, CAPASSO G, RUGGE M, FASSAN M, RIGOTTI M, CASCIONE L, BRACONI C, VALERI N., MANUNTA , PAOLO, Trevisani, F, Ghidini, M, Hahne, J, Lampis, A, Manunta, Paolo, SCIARRONE ALIBRANDI, Mt, Zagato, L, Citterio, L, Dell’Antonio, G, Montorsi, Francesco, Bertini, R, Salonia, Andrea, Briganti, A, Benigni, F, Carenzi, C, Capasso, G, Rugge, M, Fassan, M, Rigotti, M, Cascione, L, Braconi, C, and Valeri, N.

Published
2015

26. Clinical and pre-clinical biomarkers of Regorafenib (REG) efficacy in metastatic colorectal cancer (mCRC) in a phase II trial

Author

Khan, K., primary, Cunningham, D., additional, Vlachogiannis, G., additional, Hedayat, S., additional, Rata, M., additional, Koh, D-M., additional, Tunariu, N., additional, Jamin, Y., additional, Collins, D., additional, Chau, I., additional, Rao, S., additional, Watkins, D., additional, Starling, N., additional, Peckitt, C., additional, Fotiadis, N., additional, Saffery, C., additional, Hahne, J., additional, Fassan, M., additional, Braconi, C., additional, and Valeri, N., additional

Published
2017
Full Text
View/download PDF

28. KRAS mutations in circulating tumour DNA (ctDNA) in MRI-defined, high-risk, locally-advanced rectal cancer (LARC) patients (pts) from the EXPERT-C trial

Author

Sclafani, F., Chau, I., Cunningham, D., Vlachogiannis, G., Eltahir, Z., Lampis, A., Braconi, C., Kalaitzaki, E., De Castro, D. Gonzalez, Wotherspoon, A., Capdevila, J., Glimelius, Bengt, Cervantes, A., Begum, R., Lote, H., Mentrasti, G., Hahne, J. C., Tait, D., Brown, G., Valeri, N., Sclafani, F., Chau, I., Cunningham, D., Vlachogiannis, G., Eltahir, Z., Lampis, A., Braconi, C., Kalaitzaki, E., De Castro, D. Gonzalez, Wotherspoon, A., Capdevila, J., Glimelius, Bengt, Cervantes, A., Begum, R., Lote, H., Mentrasti, G., Hahne, J. C., Tait, D., Brown, G., and Valeri, N.

Published
2016
Full Text
View/download PDF

31. 731P - Liver metastases (LM) from intrahepatic cholangiocarcinoma (iCCA): Outcomes from the European Network for the study of cholangiocarcinoma (ENS-CCA) registry and implications on current American Joint Committee on Cancer (AJCC) staging

Author

Lamarca, A., Santos, A., Utpatel, K., La Casta, A., Stock, S., Forner, A., Adeva Alfonso, J., Folseraas, T., Fabris, L., Macias, R., Krawczyk, M., Cardinale, V., Braconi, C., Alvaro, D., Evert, M., Bañales, J., and Valle, J.W.

Published
2019
Full Text
View/download PDF

32. PD-003 - Identification of a nanostring signature that differentiates early pancreatic cancers according to stromal composition and predicts clinical outcome

Author

Sclafani, F., Cascione, L., Cunningham, D., Young, K., Carotenuto, P., Fassan, M., Salati, M., Lanese, A., Berenguer Pina, J., Kouvelakis, K., Vendrell, I., Said-Huntingford, I., Previdi, M., Begum, R., Gillbanks, A., Hedayat, S., Sadanandam, A., Lampis, A., Hahne, J., Valeri, N., Chau, I., and Braconi, C.

Published
2019
Full Text
View/download PDF

33. Investigating the feasibility of precision medicine in gastrointestinal cancers

Author

Moorcraft, S.Y., primary, Gonzalez De Castro, D., additional, Cunningham, D., additional, Walker, B., additional, Jones, T., additional, Peckitt, C., additional, Wilson, S. Hulkki, additional, Wotherspoon, A., additional, Te Mendes, L. Sixeira, additional, Begum, R., additional, Eltahir, Z., additional, Yuan, L., additional, Gillbanks, A., additional, Baratelli, C., additional, Valeri, N., additional, Gerlinger, M., additional, Braconi, C., additional, Chau, I., additional, Watkins, D., additional, and Starling, N., additional

Published
2016
Full Text
View/download PDF

35. Prognostic value of the immune-related transcriptome in biliary tract cancers

Author

Ghidini, M., primary, Cascione, L., additional, Lampis, A., additional, Pandolfo, R., additional, Carotenuto, P., additional, Trevisani, F., additional, Hahne, J.C., additional, Zito, D., additional, Guzzardo, V., additional, Zerbi, A., additional, Torzilli, G., additional, Roncalli, M., additional, Rimassa, L., additional, Santoro, A., additional, Fassan, M., additional, Valeri, N., additional, and Braconi, C., additional

Published
2016
Full Text
View/download PDF

36. KRAS mutations in circulating tumour DNA (ctDNA) in MRI-defined, high-risk, locally-advanced rectal cancer (LARC) patients (pts) from the EXPERT-C trial

Author

Sclafani, F., primary, Chau, I., additional, Cunningham, D., additional, Vlachogiannis, G., additional, Eltahir, Z., additional, Lampis, A., additional, Braconi, C., additional, Kalaitzaki, E., additional, De Castro, D. Gonzalez, additional, Wotherspoon, A., additional, Capdevila, J., additional, Glimelius, B., additional, Cervantes, A., additional, Begum, R., additional, Lote, H., additional, Mentrasti, G., additional, Hahne, J.C., additional, Tait, D., additional, Brown, G., additional, and Valeri, N., additional

Published
2016
Full Text
View/download PDF

37. HSP-90 Inhibition is a Promising Therapeutic Strategy in Cholangiocarcinoma and MIR-21 may Serve as a Biomarker of Sensitivity

Author

Lampis, A., primary, Cascione, L., additional, Burke, R., additional, Clarke, P., additional, Simbolo, M., additional, Scarpa, A., additional, Bosma, E., additional, Yu, S., additional, Cole, R., additional, Stubbs, M., additional, Sharp, S., additional, van Montfort, R., additional, Hahne, J., additional, Fassan, M., additional, Workman, P., additional, Valeri, N., additional, and Braconi, C., additional

Published
2016
Full Text
View/download PDF

38. Prognostic role of the LCS-6 KRAS variant in locally advanced rectal cancer : Results of the EXPERT-C trial

Author

Sclafani, F., Chau, I., Cunningham, D., Peckitt, C., Lampis, A., Hahne, J. C., Braconi, C., Tabernero, J., Glimelius, Bengt, Cervantes, A., Begum, R., De Castro, D. Gonzalez, Wilson, S. Hulkki, Eltahir, Z., Wotherspoon, A., Tait, D., Brown, G., Oates, J., Valeri, N., Sclafani, F., Chau, I., Cunningham, D., Peckitt, C., Lampis, A., Hahne, J. C., Braconi, C., Tabernero, J., Glimelius, Bengt, Cervantes, A., Begum, R., De Castro, D. Gonzalez, Wilson, S. Hulkki, Eltahir, Z., Wotherspoon, A., Tait, D., Brown, G., Oates, J., and Valeri, N.

Abstract

Meeting Abstract: 2188

Published
2015

41. Retrospective analysis of the role of adjuvant chemotherapy and microRNAs expression in resected cholangiocarcinomas (CCAs)

Author

Ghidini, M., primary, Trevisani, F., additional, Fassan, M., additional, Cascione, L., additional, Hahne, J.C., additional, Lampis, A., additional, Cheong, I.H., additional, Scarpa, A., additional, Vicentini, C., additional, Zerbi, A., additional, Torzilli, G., additional, Roncalli, M., additional, Rimassa, L., additional, Valeri, N., additional, Santoro, A., additional, and Braconi, C., additional

Published
2015
Full Text
View/download PDF

42. 2188 Prognostic role of the LCS-6 KRAS variant in locally advanced rectal cancer: Results of the EXPERT-C trial

Author

Sclafani, F., primary, Chau, I., additional, Cunningham, D., additional, Peckitt, C., additional, Lampis, A., additional, Hahne, J.C., additional, Braconi, C., additional, Tabernero, J., additional, Glimelius, B., additional, Cervantes, A., additional, Begum, R., additional, Castro, D. Gonzalez De, additional, Hulkki Wilson, S., additional, Eltahir, Z., additional, Wotherspoon, A., additional, Tait, D., additional, Brown, G., additional, Oates, J., additional, and Valeri, N., additional

Published
2015
Full Text
View/download PDF

43. P0282 : The long non coding RNA UC.158 modulates growth of Wnt/β;-catenin driven hepatocellular carcinoma (HCC)

Author

Cheong, I.H., primary, Lampis, A., additional, Fassan, M., additional, Paulus-Hock, V., additional, Vicentini, C., additional, Hahne, J., additional, Cascione, L., additional, Quagliata, L., additional, Jamieson, T., additional, Athineos, D., additional, Veronese, A., additional, Visone, R., additional, Murgia, C., additional, Ferrari, G., additional, Evans, T.R., additional, Feng, G.J., additional, Dale, T., additional, Boulter, L., additional, Guest, R., additional, Forbes, S., additional, Negrini, M., additional, Terracciano, L., additional, Scarpa, A., additional, Patel, T., additional, Workman, P., additional, Sansom, O., additional, Valeri, N., additional, and Braconi, C., additional

Published
2015
Full Text
View/download PDF

47. P64 THE ULTRACONSERVED NON CODING RNA UC.158 IS DOWNSTREAM OF THE WNT/b-CATENIN PATHWAY IN LIVER CANCERS

Author

Paulus-Hock, V., primary, Lampis, A., additional, Ferrari, G., additional, Boulton, L., additional, Guest, R., additional, Athineos, D., additional, Jamieson, T., additional, Veronese, A., additional, Visone, R., additional, Evans, R., additional, Feng, G.J., additional, Dale, T., additional, Negrini, M., additional, Forbes, S., additional, Patel, T., additional, Sansom, O., additional, Valeri, N., additional, and Braconi, C., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results